Skip to main content
SpringerLink
Log in

New therapeutic approaches based on gene transfer techniques

  • Published:
Springer Seminars in Immunopathology Aims and scope Submit manuscript

Conclusions

The experimental results from the use of gene transfer techniques for cancer therapy are promising but, at the same time, somewhat perplexing. Progress will depend on the further understanding of the biology of tumour interaction with the immune system, as this would be important for the development of optimal strategies for harnessing an effective immune response against tumours. On the other hand, extrapolation from laboratory models to human disease is limited and, therefore, there is a requirement for well-planned clinical studies. Although numerous viral and non-viral methods of gene transfer are available currently, in order to achieve realistic therapeutic efficacy for in vivo gene therapy of cancer there is a pressing need to improve on existing vectors. Hopefully, effort being directed at this objective will result in the development of safer, more highly efficient and well-targeted vectors which in turn will lead to the reality of wide clinical application.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Addison CL, Braciak T, Ralston R, Muller WJ, Gauldie J, Graham FL (1995) Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model. Proc Natl Acad Sci USA 92: 8522

    Google Scholar 

  2. Ali M, Lemoine NR, Ring CJA (1994). The use of DNA viruses as vectors for gene therapy. Gene Ther 1: 367

    Google Scholar 

  3. Allison JP, Hurwitz AA, Leach DR (1995) Manipulation of costimulatory signals to enhance antitumor T-cell responses. Curr Opin Immunol 7: 682

    Google Scholar 

  4. Allison JP, Krummel MF (1995) The Yin and Yang of T cell costimulation. Science 270: 932

    Google Scholar 

  5. Azuma M, Ito D, Yagita H, Okumura K, Phillips JH, Lanier LL, Somoza C (1993) B70 antigen is a second ligand for CTLA-4 and CD28. Nature 366: 76

    Google Scholar 

  6. Bannerji R, Arroyo CD, Cordon-Cardo C, Gilboa E (1994) The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity. J Immunol 152: 2324

    Google Scholar 

  7. Barba D, Hardin J, Sadelain M, Gage F (1994) Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc Natl Acad Sci USA 91: 4348

    Google Scholar 

  8. Baskar S, Glimcher L, Nabavi N, Jones R, Ostrand-Rosenberg S (1995) Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumorbearing mice. J Exp Med 181: 619

    Google Scholar 

  9. Baum C, Hegewisch-Becker S, Eckert HG, Stocking C, Ostertag W (1995) Novel retroviral vectors for efficient expression of the multidrug resistance (mdr-1) gene in early hematopoietic cells. J Virol 69: 7541

    Google Scholar 

  10. Baum C, Margison GP, Eckert H-G, Fairbairn LJ, Ostertag W, Rafferty JA (1996) Gene transfer to augment the therapeutic index of anticancer chemotherapy. Gene Ther 3: 1

    Google Scholar 

  11. Bett AJ, Haddara W, Prevec L, Graham FL (1994) An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci USA 91: 8802

    Google Scholar 

  12. Bi WL, Parysek LM, Wamick R, Stambrook PJ (1993) In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. Hum Gene Ther 4: 725

    Google Scholar 

  13. Blankenstein T (1994) Increasing tumour immunogenicity by genetic modification. Eur J Cancer 30A: 1182

    Google Scholar 

  14. Bluestone JA (1995) New perspectives of C1328-137-mediated T cell costimulation. Immunity 2: 555

    Google Scholar 

  15. Bonnekoh B, Greenhalgh DA, Bundman DS, Eckhardt JN, Longley MA, Chen SH, Woo SLC, Roop DR (1995) Inhibition of melanoma growth by adenovirul-mediated HSV thymidine kinase gene transfer in vivo. J Invest Dermatol 104: 313

    Google Scholar 

  16. Boon T, Cerottini J-C, Van den Eynde B, van der Bruggen P, Van Pel A (1994) Tumor antigens recognised by lymphocytes. Annu Rev Immunol 12: 337

    Google Scholar 

  17. Bronte V, Tsung K, Rao JB, Chen PW, Wang M, Rosenberg SA, Restifo NP (1995) IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J Immunol 154: 5282

    Google Scholar 

  18. Carducci MA, Ayyagari SR, Sanda MG, Simons JW (1995) Gene therapy for human prostate cancer. Cancer 75: 2013

    Google Scholar 

  19. Cavallo F, Giovarelli M, Gulino A, Vacca A, Stoppaciaro A, Modesti A, Forni G (1992) Role of neutrophils and CD4+ T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene. J Immunol 149: 3627

    Google Scholar 

  20. Cayeux S, Beck C, Aicher A, Dorken B, Blankenstein T (1995) Tumor cells cotransfected with interleukin-7 and B7.1 genes induce CD25 and CD28 on tumor-infiltrating T lymphocytes and are strong vaccines. Eur J Immunol 25: 2325

    Google Scholar 

  21. Cayeux S, Beck C, Dorken B, Blankenstein T (1996) Coexpression of interleukin-4 and B7.1 in murine tumor cells leads to improved tumor rejection and vaccine effect compared to single gene transfectants and a classical adjuvant. Hum Gene Ther 7: 525

    Google Scholar 

  22. Chen L, Ashe S, Brady WA, Hellstrom I, Hellstrom KE, Ledbetter JA, McGowan P, Linsley P (1992) Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71: 1093

    Google Scholar 

  23. Chen L, McGowan P, Ashe S, Johnson J, Li Y, Hellstrom I, Hellstrom K (1994) Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med 179: 523

    Google Scholar 

  24. Chen S-H, Chen XHL, Wanf Y, Kosai K-I, Finegold MJ, Rich SS, Woo SLC (1995) Combination gene therapy for liver metastasis of colon carcinoma in vivo. Proc Natl Acad Sci USA 92: 2577

    Google Scholar 

  25. Clayman GL, El-Naggar AK, Roth JA, Zhang W-W, Goepfert H, Taylor DL, Liu T-J (1995) In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res 55: 1

    Google Scholar 

  26. Colak A, Goodman JC, Chen SH, Woo SLC, Grossman RG, Shine HD (1995) Adenovirus-mediated gene therapy in an experimental model of breast cancer metastatic to the brain. Hum Gene Ther 6: 1317

    Google Scholar 

  27. Colombo MP, Form G (1994) Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol Today 15: 48

    Google Scholar 

  28. Colombo MP, Modesti A, Parmiani G, Forni G (1992) Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk. Cancer Res 52: 4853

    Google Scholar 

  29. Connors TA (1995) The choice of prodrgs for gene directed enzyme prodrug therapy of cancer. Gene Ther 2: 702

    Google Scholar 

  30. Conry RM, LoBuglio AF, Loechel F, Moore SE, Sumerel LA, Barlow DL, Curiel DT (1995) A carcinoembryonic antigen polynucleotide vaccine has in vivo antitumor activity. Gene Ther 2: 59

    Google Scholar 

  31. Consalvo M, Mullen CA, Modesti A, Musiani P, Allione A, Cavallo F, Giovarelli M, Forni G (1995) 5-Fluorocytosine-induced eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves an efficient memory. J Immunol 154: 5302

    Google Scholar 

  32. Cordier L, Duffour M-T, Sabourin J-C, Lee MG, Cabannes J, Ragot T, Perricaudet M, Haddada H (1995) Complete recovery of mice from a pre-established tumor by direct intratumoral delivery of an adenovirus vector harboring the murine IL-2 gene. Gene Ther 2: 16

    Google Scholar 

  33. Cometta K, Morgan RA, Anderson WF (1991) Safety issues related to retroviral-mediated gene transfer in humans. Hum Gene Ther 2: 5

    Google Scholar 

  34. Cosset F-L, Takeuchi Y, Battini J-L, Weiss RA, Collins MKL (1995) High-titre packaging cells producing recombinant retroviruses resistant to human serum. J Virol 69: 7430

    Google Scholar 

  35. Coughlin CM, Wysocka M, Kurzawa HL, Lee WMF, Trinchieri G, Eck SL (1995) B7-1 and interleukin 12 synergistically induce effective antitumor immunity. Cancer Res 55: 4980

    Google Scholar 

  36. Cox AL, Skipper J, Chen Y, Henderson RA, LDarrow T, Shabanowitz J, Engelhard VH, Hunt DF, Slingluff CLJ (1994) Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264: 716

    Google Scholar 

  37. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM (1992) In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256: 1550

    Google Scholar 

  38. Curiel DT, Agarwal S, Wagner E, Cotten M (1991) Adenovirs enhancement of transferrin-polylysine-mediated gene delivery. Proc Natl Acad Sci USA 88: 8850

    Google Scholar 

  39. Dalgleish AG (1994) The role of IL-2 in gene therapy. Gene Ther 1: 83

    Google Scholar 

  40. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting antitumor immunity. Proc Natl Acad Sci USA 90: 3539

    Google Scholar 

  41. Eastham JA, Hall SJ, Sehgal I, Wang J, Timme TL, Yang G, Connell-Crowley L, Elledge SJ, Zhang W-W, Harper JW, Thompson TC (1995) In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res 55: 5151

    Google Scholar 

  42. Fakhrai H, Shawler DL, Gjerset R, Naviaux RK, Koziol J, Royston I, Sobol RE (1995) Cytokine gene therapy with interleukin-2 transduced fibroblasts: effects of IL-2 dose on anti-tumor immunity. Hum Gene Ther 6: 591

    Google Scholar 

  43. Fearon ER, Pardoll DM, Itaya T, Golumbek P, Levitsky HI, Simons JW, Karasuyama H, Vogelstein B, Frost P (1990) Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60: 397

    Google Scholar 

  44. Felgner PL, Gadek TR, Holm M, Roman R, Chan HW, Wenz M, Northrop JP, Ringold GM, Danielsen M (1987) Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA 84: 7413

    Google Scholar 

  45. Freeman GJ, Gribben JG, Boussiotis VA, Ng JW, Restivo VAJ, Lombard LA, Gray GS, Nadler LM (1993) Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science 262: 909

    Google Scholar 

  46. Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL, Abraham GN (1993) The “bystander effect”: tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 53: 5274

    Google Scholar 

  47. Friedmann T, Yee JK (1995) Pseudotyped retroviral vectors for studies of human gene therapy. Nature Med 1: 275

    Google Scholar 

  48. Fujiwara T, Cai DW, Georges RN, Mukhopadhyay T, Grimm EA, Roth JA (1994) Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J Natl Cancer Inst 86: 1458

    Google Scholar 

  49. Gao X, Huang L (1995) Cationic liposome-mediated gene transfer. Gene Ther 2: 710

    Google Scholar 

  50. Gimmi CD, Freeman GJ, Gribben JG, Sugita K, Freedman AS, Morimoto C, Nadler LM (1991) Bcell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2. Proc Natl Acad Sci USA 88: 6575

    Google Scholar 

  51. Graham FL, Prevec L (1995) Methods for construction of adenovirus vectors. Mol Biotechnol 3: 207

    Google Scholar 

  52. Han X, Kasahara N, Kan YW (1995) Ligand-directed retroviral targeting of human breast cancer cells. Proc Natl Acad Sci USA 92: 9747

    Google Scholar 

  53. Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP (1992) CD28-mediated signalling costimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 356: 607

    Google Scholar 

  54. Harris JD, Gutierrez AA, Hurst HC, Sikora K, Lemoine NR (1994) Gene therapy for cancer using tumour-specific prodrug activation. Gene Ther 1: 170

    Google Scholar 

  55. Hellstrom KE, Hellstrom I, Chen L (1995) Can co-stimulated tumor immunity be therapeutically efficacious? Immunol Rev 145: 123

    Google Scholar 

  56. Hock H, Dorsch M, Kunzendorf U, Uberla K, Qin Z, Diamanstein T, Blankenstein T (1993) Vaccination with tumor cells genetically engineered to produce different cytokines: effectivity not superior to a classical adjuvant. Cancer Res 53: 714

    Google Scholar 

  57. Huang AYC, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H (1994) Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264: 961

    Google Scholar 

  58. Huber BE, Richards CA, Krenitsky TA (1991) Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy. Proc Natl Acad Sci USA 88: 8039

    Google Scholar 

  59. Hurford RK, Dranoff G, Mulligan RC, Tepper RI (1995) Gene therapy of metastatic cancer by in vivo retroviral gene targeting. Nature Genet 10: 430

    Google Scholar 

  60. Irvine KR, Rao JB, Rosenberg SA, Restifo NP (1996) Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J Immunol 156: 238

    Google Scholar 

  61. Jenkins MK (1994) The ups and downs of T cell costimulation. Immunity 1: 443

    Google Scholar 

  62. Jin X, Nguyen D, Zhanh WW, Kyritsis AP, Roth JA (1995) Cell cycle arrest and inhibition of tumor cell proliferation by the pl6INK4 gene mediated by an adenovirus vector. Cancer Res 55: 3250

    Google Scholar 

  63. Jolly D (1994) Viral vector systems for gene therapy. Cancer Gene Ther 1: 51

    Google Scholar 

  64. Karp SE, Farber A, Salo JC, Hwu P, Jaffe G, Asher AL, Shiloni E, Restifo NP, Mule JJ, Rosenberg SA (1993) Cytokine secretion by genetically modified nonimmunogenic murine fibrosarcoma. J Immunol 150: 896

    Google Scholar 

  65. Kim TS, Cohen EP (1994) Interleukin-2-secreting mouse fibroblasts transfected with genomic DNA from murine melanoma cells prolong the survival of mice with melanoma. Cancer Res 54: 2531

    Google Scholar 

  66. Kim TS, Russell SJ, Collins MKL, Cohen EP (1993) Immunization with interleukin-2-secreting allogeneic mouse fibroblasts expressing melanoma-associated antigens prolongs the survival of mice with melanoma. Int J Cancer 55: 865

    Google Scholar 

  67. Kotin RM (1994) Prospects for the use of adeno-associated virus as a vector for human gene therapy. Hum Gene Ther 5: 793

    Google Scholar 

  68. Ledley FD (1995) Nonviral gene therapy: the promise of genes as pharmaceutical products. Hum Gene Ther 6: 1129

    Google Scholar 

  69. Leeson-Wood LA, Kim WH, Kleinman HK, Weintraub BD, Mixson AJ (1995) Systemic gene therapy with p53 reduces growth and metastases of a malignant human breast cancer in nude mice. Hum Gene Ther 6: 395

    Google Scholar 

  70. Linsley P, Brady W, Grosmaire L, Aruffo A, Damle NK, Ledbetter JA (1991) Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med 173: 721

    Google Scholar 

  71. Linsley PS, Ledbetter JA (1993) The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol 11: 191

    Google Scholar 

  72. Liu Y, Liggitt D, Zhong W, Tu G, Gaensler K, Debs R (1995) Cationic liposome-mediated intravenous gene delivery. J Biol Chem 270: 24864

    Google Scholar 

  73. Mandelboim O, Berke G, Fridkin M, Feldman M, Eisenstein M, Eisenbach L (1994) CTL induction by a tumour-associated antigen octapeptide derived from a routine lung carcinoma. Nature 369: 67

    Google Scholar 

  74. Melief JM, Kast WM (1993) Potential immunogenicity of oncogene and tumor suppressor gene products. Curt Opin Immunol 5: 709

    Google Scholar 

  75. Mercola D, Cohen JS (1995) Antisense approaches to cancer gene therapy. Cancer Gene Ther 2: 47

    Google Scholar 

  76. Miller A (1992) Retroviral vectors. Curr Top Microbiol Immunol 158: 1

    Google Scholar 

  77. Miller AD (1990) Retrovirus packaging cells. Hum Gene Ther 1: 5

    Google Scholar 

  78. Miller DG, Adam MA, Miller AD (1990) Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 10: 4239

    Google Scholar 

  79. Mizoguchi H, O'Shea JJ, Longo DL, Loeffler CM, McVicar DW, Ochoa AC (1992) Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 258: 1795

    Google Scholar 

  80. Moolten F (1986) Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 46: 5276

    Google Scholar 

  81. Moolten FL (1994) Drug sensitivity (“suicide”) genes for selective cancer chemotherapy. Cancer Gene Ther 1: 279

    Google Scholar 

  82. Morgan RA, Couture L, Elroy-Stein O, Ragheb J, Moss B, Anderson WF (1992) Retroviral vectors containing putative internal ribosome entry sites: development of a polycistronic gene transfer system and applications to human gene therapy. Nucleic Acids Res 20: 1293

    Google Scholar 

  83. Mullen C, Kilstrup M, Blaese R (1992) Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc Natl Acad Sci USA 89: 33

    Google Scholar 

  84. Mullen CA, Coale MM, Lowe R, Blaese RM (1994) Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor. Cancer Res 54: 1503

    Google Scholar 

  85. Nabel G, Nabel E, Yang Z-Y, Fox B, Plautz G, Gao X, Huang L, Shu S, Gordon D, Chang A (1993) Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci USA 90: 11307

    Google Scholar 

  86. Nabel GJ, Chang A, Nabel EG, Plautz G, Fox BA, Huang L, Shu S (1992) Immunotherapy of malignancy by in vivo gene transfer into tumors. Hum Gene Ther 3: 399

    Google Scholar 

  87. Okamura H, Tsutsui H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T, Torigoe K, Okura T, Nukada Y, Hattori K, Akita K, Namba M, Tanabe F, Konishi K, Fukuda S, Kurimoto M (1995) Cloning of a new cytokine that induces IFN-γ production by T cells. Nature 378: 88

    Google Scholar 

  88. Palmer TD, Rosman GJ, Osborne WRA, Miller AD (1991) Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes. Proc Natl Acad Sci USA 88: 1330

    Google Scholar 

  89. Pang S, Taneja S, Dardashti K, Cohan P, Kaboo R, Sokoloff M, Tso CL, Dekernion JB, Belldegrun AS (1995) Prostate tissue specificity of the prostate-specific antigen promoter isolated from a patient with prostate cancer. Hum Gene Ther 6: 1417

    Google Scholar 

  90. Pardoll D (1993) New strategies for enhancing the immunogenicity of tumors. Curt Opin Immunol 5: 719

    Google Scholar 

  91. Pardoll DM, Beckerleg AM (1995) Exposing the immunology of naked DNA vaccines. Immunity 3: 165

    Google Scholar 

  92. Plautz GE, Yang Z-Y, Wu B-Y, Gao X, Huang L, Nabel GJ (1993) Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc Natl Acad Sci USA 90: 4645

    Google Scholar 

  93. Porgador A, Gansbacher B, Bannerji R, Tzehoval E, Gilboa E, Feldman M, Eisenbach L (1993) Anti-metastatic vaccination of tumor-bearing mice with IL-2-gene-inserted tumor cells. Int J Cancer 53: 471

    Google Scholar 

  94. Ram Z, Walbridge S, Heiss JD, Culver KW, Blaese RM, Oldfield EH (1994) In in vivo transfer of the human interleukin-2 gene: negative tumoricidal results in experimental brain tumors. J Neurosurg 80: 535

    Google Scholar 

  95. Rettinger SD, Kennedy SC, Wu X, Saylors RL, Hafenrichter DG, Flye MW, Ponder KP (1994) Liver-directed gene therapy: quantitative evaluation of promoter elements by using in vivo retroviral transduction. Proc Natl Acad Sci USA 91: 1460

    Google Scholar 

  96. Richards CA, Huber BE (1993) Generation of a transgenic model for retrovirus-mediated gene therapy for hepatocellular carcinoma is thwarted by the lack of transgene expression. Hum Gene Ther 4: 143

    Google Scholar 

  97. Rosenberg SA (1992) The immunotherapy and gene therapy of cancer. J Clin Oncol 10: 180

    Google Scholar 

  98. Russell SJ (1994) Replicating vectors for gene therapy of cancer: risks, limitations and prospects. Eur J Cancer 30A: 1165

    Google Scholar 

  99. Russell SJ, Brandenburger A, Flemming CL, Collins MKL, Rommelaere J (1992) Transformation-dependent expression of interleukin genes delivered by recombinant parvovirus. J Virol 66: 2821

    Google Scholar 

  100. Russell SJ, Eccles S, Flemming C, Johnson CA, Collins MKL (1991) Decreased tumorigenicity of a transplantable rat sarcoma following transfer and expression of an IL-2 cDNA. Int J Cancer 47: 244

    Google Scholar 

  101. Saito S, Bannerji R, Gansbacher B, Rosenthal F, Romanenko P, Heston W, Fair W, Gilboa E (1994) Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines. Cancer Res 54: 3516

    Google Scholar 

  102. Salmons B, Gunzburg WH (1993) Targeting of retroviral vectors for gene therapy. Hum Gene Ther 4: 129

    Google Scholar 

  103. Salvadori S, Gansbacher B, Wernick I, Tirelli S, Zier K (1995) B7-1 amplifies the response to interleukin-2-secreting tumor vaccines in vivo, but fails to induce a response by naive cells in vitro. Hum Gene Ther 6: 1299

    Google Scholar 

  104. Santodonato L, Ferrantini M, Gabriele L, Proietti E, Venditti M, Musiani P, Modesti A, Modica A, Lupton SD, Belardelli F (1996) Cure of mice with established metastatic Friend leukaemia cell tumors by a combined therapy with tumor cells expressing both interferon-al and herpes simplex thymidine kinase followed by ganciclovir. Hum Gene Ther 7: 1

    Google Scholar 

  105. Schmidt W, Schweighoffer T, Herbst E, Maass G, Berger M, Schilcher F, Schaffner G, Birnstiel ML (1995) Cancer vaccines: the interleukin 2 dosage effect. Proc Natl Acad Sci USA 92: 4711

    Google Scholar 

  106. Sorrentino BP, Brandt SJ, Bodine D, Gottesman M, Pastan I, Cline A, Nienhuis AW (1992) Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. Science 257: 99

    Google Scholar 

  107. Sugaya S, Fujita K, Kikuchi A, Ueda H, Takakuwa K, Kodama S, Tanaka K (1996) Inhibition of tumor growth by direct intratumoral gene transfer of herpes simplex virus thymidine kinase gene with DNA-liposome complexes. Hum Gene Ther 7: 223

    Google Scholar 

  108. Sun WH, Burkholder JK, Sun J, Culp J, Turner J, GLu X, Pugh TD, Ershler WB, Yang N-S (1995) In vivo cytokine gene transfer by gene gun reduces tumor growth in mice. Proc Natl Acad Sci USA 92: 2889

    Google Scholar 

  109. Tahara H, Lotze MT (1995) Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer. Gene Ther 2: 96

    Google Scholar 

  110. Tahara H, Zitgovel L, Storkus WJ, Zeh HJ III, McKinney TG, Schreiber RD, Gubler U, Robbins PD, Lotze MT (1995) Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J Immunol 154: 6466

    Google Scholar 

  111. Takeuchi Y, Cosset FL, Lachmann PJ, Okada H, Weiss RA, Collins MKL (1994) Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell. J Virol 68: 8001

    Google Scholar 

  112. Tepper RI, Mule JJ (1994) Experimental and clinical studies of cytokine gene-modified tumor cells. Hum Gene Ther 5: 153

    Google Scholar 

  113. Thierry AR, Lunardi-Iskandar Y, Bryant JL, Rabinovich P, Gallo RC, Mahan LC (1995) Systemic gene therapy: biodistribution and long-term expression of a transgene in mice. Proc Natl Acad Sci USA 92: 9742

    Google Scholar 

  114. Thompson CB (1995) Distinct roles for the costimulatory ligands B7-1 and B7-2 in T helper cell differentiation? Cell 81: 979

    Google Scholar 

  115. Townsend SE, Allison JP (1993) Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 259: 368

    Google Scholar 

  116. Trinchieri G (1995) Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 13: 251

    Google Scholar 

  117. Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, Dwarki VJ, Gromkowski SH, Deck RR, DeWitt CM, Friedman A, Hawe LA, Leander KR, Artinez DM, Perry HC, Shiver JW, Montgomery DL, Liu MA (1993) Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259: 1745

    Google Scholar 

  118. Van den Eynde B, Brichard VG (1995) New tumor antigens recognized by T cells. Curt Opin Immunol 7: 674

    Google Scholar 

  119. Van Pel A, Boon T (1982) Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis. Proc Natl Acad Sci USA 79: 4718

    Google Scholar 

  120. Vieweg J, Rosenthal F, Bannerji R, Heston W, Fair W, Gansbacher B, Gilboa E (1994) Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines. Cancer Res 54: 1760

    Google Scholar 

  121. Vile R, Miller N, Chemajovsky Y, Hart I (1994) A comparison of the properties of different retroviral vectors containing the marine tyrosinase promoter to achieve transcriptionally targeted expression of the HSVtk or IL-2 genes. Gene Ther 1: 307

    Google Scholar 

  122. Vile R, Russell SJ (1994) Gene transfer technologies for the gene therapy of cancer. Gene Ther 1: 88

    Google Scholar 

  123. Vile RG (1994) Tumor-specific gene expression. Semin Cancer Biol 5: 429

    Google Scholar 

  124. Vile RG, Chong H, Dorudi S (1996) The immunosurveillance of cancer: specific and non-specific mechanisms. In: Dalgleish AC, Browning MJ (eds) Tumor immunology. Cambridge University Press, New York, pp 7–38

    Google Scholar 

  125. Vile RG, Diaz RM, Miller N, Mitchell S, Tuszyanski A, Russell SJ (1995) Tissue-specific gene expression from Mo-MLV retroviral vectors with hybrid LTRs containing the murine tyrosinase enhanancer/promoter. Virology 214: 307

    Google Scholar 

  126. Vile RG, Hart IR (1993) In vitro and in vivo targeting of gene expression to melanoma cells. Cancer Res 53: 962

    Google Scholar 

  127. Vile RG, Hart IR (1993) Use of tissue-specific expression of the herpes simplex thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA. Cancer Res 53: 3860

    Google Scholar 

  128. Vile RG, Nelson JA, Castleden S, Chong H, Hart IR (1994) Systemic gene therapy of routine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res 54: 6228

    Google Scholar 

  129. Vile RG, Russell SJ (1995) Retroviruses as vectors. Br Med Bull 51: 12

    Google Scholar 

  130. Wagner E, Zatloukal K, Cotten M, Kirlappos H, Mechtler K, Curiel DT, Birnstiel ML (1992) Coupling of adenovirus to transfertin-polylysine/DNA complexes greatly enhances receptor-mediated gene delivery and expression of transfected genes. Proc Natl Acad Sci USA 89: 6099

    Google Scholar 

  131. Wang B, Merva M, Dang K, Ugen KE, Williams WV, Weiner DB (1995) Immunization by direct DNA inoculation induces rejection of tumor cell challenge. Hum Gene Ther 6: 407

    Google Scholar 

  132. Wei MX, Tamiya T, Hurford RK, Boviatsis EJ, Tepper RI, Chiocca A (1995) Enhancement of interleukin-4 mediated tumor regression in athymic mice by in situ retroviral gene transfer. Hum Gene Ther 1995: 437

    Google Scholar 

  133. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL (1990) Direct gene transfer into mouse muscle in vivo. Science 247: 1465

    Google Scholar 

  134. Xiang Z, Ertl HC (1995) Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity 2: 129

    Google Scholar 

  135. Yang G, Hellstrom KE, Hellstrom I, Chen L (1995) Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules. J Immunol 154: 2794

    Google Scholar 

  136. Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E, Wilson JM (1994) Cellular immunity to viral antigens limits El-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 91: 4407

    Google Scholar 

  137. Yang Z-Y, Perkins ND, Ohno T, Nabel EG, Nabel GJ (1995) The p21 cyclin-dependent kinase inhibitor suppresses tumorigenicity in vivo. Nature Med 1: 1052

    Google Scholar 

  138. Zhang Y, Mukhopadhyay T, Donehower LA, Georges RN, Roth JA (1993) Retroviral vector-mediated transduction of K-ras antisense RNA into human lung cancer cells inhibits expression of the malignant phenotype. Hum Gene Ther 4: 451

    Google Scholar 

  139. Zhu N, Liggitt D, Liu Y, Debs R (1993) Systemic gene expression after intravenous DNA delivery into adult mice. Science 261: 209

    Google Scholar 

  140. Zier KS, Gansbacher B (1995) The impact of gene therapy on T cell function in cancer. Hum Gene Ther 6: 1259

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Imperial Cancer Research Fund Laboratory of Cancer Gene Therapy, The Rayne Institute, St. Thomas' Hospital, SE1 7EH, London, UK

    Heung Chong & Richard G. Vile

Authors
  1. Heung Chong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard G. Vile
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chong, H., Vile, R.G. New therapeutic approaches based on gene transfer techniques. Springer Semin Immunopathol 18, 149–170 (1996). https://doi.org/10.1007/BF00820663

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00820663

Keywords

Search

Navigation